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The endocrine system controls harmonious
development, growth, and homeostasis.
Although the range of normal values for
hormones is often quite wide, certain ones,
such as the steroidal hormones, function
physiologically at extremely low concentra-
tions, in the nanomolar (parts per billion)
to picomolar [parts per trillion (ppt)] range.
It is well established in clinical science that
even mild hormonal imbalances can be
associated with significant adverse health
effects. Examples of health outcomes from
mild endocrine perturbation can be instruc-
tive for understanding the complexity of
testing hormonally active compounds. This
is especially true when evaluating whether
environmentally relevant low doses of syn-
thetic chemicals can have biologic effects
and when considering the appropriateness
of applying toxicologic thresholds to
hormonally mediated events. 
One of the most controversial issues in
toxicology is whether exposure to low doses
of endocrine-disrupting chemicals (EDCs)
can cause adverse health consequences. The
term endocrine-disrupting chemicals here
refers to synthetic or natural chemicals that
mimic or interfere with the natural hor-
mones that control development, reproduc-
tion, and function. Unfortunately, much of
this debate remains theoretical because
existing data are scant, controversial, and
limited to a small number of chemicals (1).
Furthermore, defining what constitutes a
low dose is a challenge because such a defin-
ition depends on the context (toxicologic,
pharmacologic, physiologic, or environmen-
tal). To some extent, clinical thresholds in
endocrinology may provide guidance for
evaluating toxicologic thresholds because
they can show where perturbation in hor-
monal levels may not be inherently adverse
but can be a risk factor for the development
of clearly adverse health outcomes. 
To address these problems, we examine
the literature relating to endocrine systems in
pubertal and adult humans. We ﬁrst describe
examples of shifts in normal hormonal values
associated with a physiologic change in
phenotype. We then show the adaptive
endocrine consequences of age, stress, nutri-
tion, exercise, or chronic disease. Next, we
focus on the adverse consequences of mild
endocrine diseases in pubertal and adult
humans and on the deleterious systemic
effects of gonadal imbalance. We then dis-
cuss the different thresholds in medicine—
diagnostic or therapeutic—leading to the
no-threshold concept pertaining to the speci-
ficity of the endocrine systems. Building on
these facts, we address the implications for
testing chemicals for their endocrine impact,





Role of Estrogen Before and During
Puberty 
Estrogen has a biphasic effect on epiphyseal
growth. Whereas low levels of estradiol (E2)
favor the pubertal growth spurt, higher
pubertal levels cause fusion of the epiphyses,
thus stopping growth (2). The administration
of a low dose of E2 increases serum concen-
tration from < 1 pg/mL to 4 pg/mL (ppt) and
increases prepubertal growth rates in both
boys and girls by more than 60%, suggesting
that the optimal growth-promoting effect of
E2 occurs at 4 pg/mL (2). By way of compari-
son, adult levels of E2 range from 20 to > 200
pg/mL in women and are < 50 pg/mL in
men. Thus, prepubertal bone plates are
exquisitely sensitive to E2, responding maxi-
mally at levels up to 50 times lower than
adult levels. 
The recent development of ultrasensitive
assays for measuring hormone levels has
demonstrated that prepubertal girls have lev-
els of E2 eight times higher than those of pre-
pubertal boys (0.6 ± 0.6 pg/mL vs. 0.08 ± 0.2
pg/mL), and this gap widens in the peripu-
bertal period (2). Sex differences in the tim-
ing and duration of the pubertal growth spurt
are attributed mostly to the earlier increase
and sharper rise in E2 levels that occur in
girls. Because girls reach the signiﬁcant level
of 4 pg/mL E2 earlier than boys, they have an
earlier growth spurt. Because the levels of E2
rise sharply, fusion of epiphyses also occurs
earlier in girls, creating a shorter growth spurt
and lower ﬁnal height compared to boys (2).
Hormonal Changes Occurring during
the Menstrual Cycle
The menstrual cycle is a physiologic process
that occurs regularly from puberty to
menopause. As a result, the ovary secretes
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variable amounts of estradiol and proges-
terone under tight hypothalamo-pituitary
control (3). There are two distinct phases:
The follicular phase is characterized by rising
levels of estrogens and low levels of proges-
terone, leading to the maturation of a domi-
nant follicle and ovulation, announced by a
peak of luteinizing hormone (LH). The luteal
phase prepares the uterus for potential
implantation. The phenotypic consequences
during these two phases depend on concen-
trations and timing (3). Indeed, the marked
changes in hormonal levels, albeit within
physiologic ranges, cause important modiﬁca-
tions in target organs such as the vagina,
uterus (already evident on a simple pap
smear), ovary, and breast, as well as changes
in thermoregulation (4,5).
It would be easy to overlook the effect(s)
of EDCs because of the vulnerability of the
endocrine system to stressors unrelated to
EDC exposure as well as underlying condi-
tions. Sexual difference is obvious for some
diseases, with incidence greater in women
than in men; furthermore, the incidence of
disease seems inﬂuenced by the woman’s hor-
monal status (puberty, pregnancy and post-
partum period, or menopause). This is
particularly true for autoimmune diseases
such as Graves disease or Hashimoto thy-
roiditis (6), as well as rheumatoid arthritis
and systemic lupus erythematosus, for exam-
ple (7). It is well known that pregnancy is
associated with change in immune response,
followed by a frequent rebound postpartum,
depending on the type of autoimmune dis-
ease (6,7). These changes in the immune sys-
tem are likely due to a shift in cytokine
balance secondary to hormonal changes
(estrogen, progesterone, and/or cortisol) (7).
Furthermore, clinicians have long recog-
nized that some medical conditions, such as
migraines, epilepsy, asthma, and even diabetes
control, are influenced by normal menstrual
cycles (8). For example, it is possible that
estrogen, through its actions on the hip-
pocampus, could affect seizure activity (9).
Although the possible protective effect of
estrogens against Alzheimer’s disease is under
study, it has also been suggested that mild
variations in cognitive function occur during
the menstrual cycle (10). These effects are not
global but target verbal memory and sexually
dimorphic cognitive skills such as verbal artic-
ulation and ﬁne motor skills. However, these
effects have been identiﬁed in an experimental
laboratory setting and their clinical signifi-
cance is debatable (10). Finally, the premen-
strual syndrome includes an array of cyclical
mood disorders that have been linked to alter-
ations in serotonergic activity in the central
nervous system related to the menstrual cycle
(11). In this case, the respective inﬂuence of




Reproduction is particularly sensitive to
endogenous and exogenous disruption in both
sexes, but disruption has been documented
more frequently among women. Additionally,
it has been demonstrated (12) that the
gonadal axis is highly sophisticated, with a
precise set of regulatory mechanisms, whereby
its function changes under certain conditions.
Current knowledge about several adaptations
to changing conditions can provide models of
what might occur as a result of exposure to
EDCs. For example, if a woman is very young
or very old (13–21), exercises intensely
(22–23), has not enough food (24–29), is
stressed (30–33), or is sick (28,34–38), the
delicate balance of the hypothalamo–
pituitary–ovarian axis is altered, impairing or
suppressing ovulation. Thus, from an adaptive
point of view, it is clear that there is no advan-
tage for a woman to be pregnant in situations
where the outcome for the mother or the fetus
is not optimal. 
Age
The hormonal changes occurring during a
woman’s reproductive life span are well
known. Menstrual irregularity is common at
both ends of a woman’s reproductive life. In
adolescence, menstrual irregularities may
stem from an immature gonadal axis (13). In
perimenopause, the irregularity reflects pro-
gressive ovarian failure and is associated with
a dramatic decrease in fertility (14). In adoles-
cence and premenopause, the suboptimal
hormonal setting may produce poorer preg-
nancy outcome, even though in teenage
mothers the outcome also may be inﬂuenced
by adverse economic circumstances (15).
There is a U-shaped relationship between
maternal age and low birth weight: Women
under 15 and above 40 years of age are at
higher risk than women between 25 and 29
years of age (15).
Fecundity of women of advanced repro-
ductive age has been studied specifically
because of the sociologic changes that have
led many women to postpone starting a
family. Recent work (16–19), boosted by
the research in medically assisted techniques,
has allowed a better understanding of the dif-
ficulty to conceive. The premenopausal
changes are associated with a rise in follicle-
stimulating hormone (FSH) levels and a
decline in ovarian inhibin B secretion.
Interestingly, fertility becomes compromised
even before cycle irregularity, likely because
of oocyte dysfunction (16). Some additional
decrease in uterine function has been sug-
gested (17) that can cause decreased implan-
tation and pregnancy loss. Experience from
in vitro fertilization in women of advanced
reproductive age shows that the rate of suc-
cessful pregnancy decreases after 35 and more
sharply after 40. Studies with oocytes from
young women donors suggest that oocyte
dysfunction is indeed the primary culprit
(18). Endocrine markers have been used to
predict fecundity in women of advanced
reproductive age. For example, single mea-
surements of estradiol (> 80 pg/mL) and FSH
(> 13 mIU/mL), as measured at day 3 of the
menstrual cycle, could have useful negative
prognostic value (19).
Pregnancy in older women is more often
complicated by glucose intolerance and hyper-
tension (20). This, of course, has deleterious
consequences on the fetus: Indeed, globally
the perinatal outcome seems worse than in
women younger than 40 (21). Preterm deliv-
ery was observed more frequently (18.5 vs.
11.7%), and low and very low birth weight
occurred more often. The prevalence of
macrosomia was also higher (8 vs. 4.8%),
probably because of the increased incidence of
glucose intolerance. Finally, newborn mortal-
ity (3.3 vs. 1.6%) and morbidity (20.4 vs.
11.4%) were increased (21).
Exercise
Chronic extensive exercise is well known to
alter the menstrual cycle (22), though with
marked individual variation. Menstrual disor-
ders resulting from exercise include delayed
menarche, short or inadequate luteal phases,
and even secondary amenorrhea. This can
cause infertility, which may be reversible,
however, when training ceases. Exercise alters
the pulsatile release of gonadotropin-releasing
hormone (GnRH) and induces lasting
increase in cortisol and endorphins. These
changes may be viewed as a functionally adap-
tive phenomenon—an energy-saving strategy
to protect more important biologic processes.
Indeed, basal metabolic rate and caloric intake
increase during the luteal phase, so there is a
metabolic cost of maintaining an ovulation
and an advantage of eliminating it under cer-
tain circumstances (22). In addition, some
alterations in thyroid function are induced by
exercise (23). Chronic intense training in
women athletes with menstrual cyclicity is
accompanied by an isolated decrease in thy-
roxine (T4) levels. However, in athletes with
amenorrhea, all the thyroid hormones [T4,
free T4, tri-iodothyronine (T3), free T3, and
reverse T3 (rT3)] are decreased, whereas
thyroid-stimulating hormone or thyrotropin
(TSH) is normal in basal condition but is less
responsive to a thyrotropin-releasing hormone
(TRH) challenge. This suggests a central
mechanism, including an impairment of the
hypothalamo–pituitary–thyroid axis along
with the hypothalamo–pituitary–ovarian axis
during chronic exercise (23).
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Starvation 
Starvation or reduced caloric intake causing
a negative energy balance disrupts the
gonadal axis. In women, delayed menarche
and primary or secondary amenorrhea are
classic in anorexia nervosa and starvation,
although anorexia nervosa is a complex dis-
order that involves both nutritional and psy-
chologic components that can affect the
gonadal axis (24). 
The negative impact of low caloric intake
on reproduction may be seen as a homeo-
static adjustment that restricts unnecessary
energy expenditure (25). The endocrine
effects include an increase in corticotropin-
releasing factor (CRF), with its negative effect
on gonadotropins (particularly LH pulsatil-
ity), a decrease in TRH synthesis, and an
increase in growth hormone (GH) secretion.
The mechanism of increase in GH may not
be central because insulin-like growth factor
is normal or low, suggesting a more periph-
eral defect (24). Starvation and fasting also
quickly induce a decrease in TRH and T3
levels (T3 and rT3) (26), with a change in
deiodinase activity. These hormonal changes
are corrected by the administration of leptin,
a hormone secreted by adipose tissue, which
is a barometer of adipose tissue activity (25). 
There is a link between the gonadal axis
and body fat content (24) whereby gonadal
dysfunction occurs mainly under a specific
weight threshold (loss of 10–15% of body
weight) (27). Poor nutritional status is also
linked to increased risk of maternal mortality
and low birth weight, and malnourished pop-
ulations are more susceptible to chronic ill-
nesses that may also affect reproduction (28).
Experimental work helps clarify the mecha-
nisms involved. For example, in male rats,
complete fasting for 4 days decreases LH and
FSH by 30% and testosterone serum levels by
42%. Furthermore, the suppression of
pituitary–testicular function is reversed by
pulsatile GnRH substitution (29).
Stress
Stress is another factor with a strong impact
on the gonadal axis because it causes an
increase of CRF and β-endorphin in the
hypothalamus, inhibiting gonadotropins,
oxytocin, and vasopressin (30). In addition,
glucocorticoids suppress the secretion of LH
by the pituitary and of estradiol and proges-
terone by the ovary, and induce target tissues
resistant to estradiol (31). In women, cycling
disturbance or even amenorrhea can occur
during stress, as can impairment of parturi-
tion or lactation (30). Prevention of concep-
tion could be viewed as an advantage at a
time when the environment may be hostile to
the survival of both mother and young (30).
In men, evidence suggests that mild-to-severe
emotional stress reduces testosterone levels
and perhaps interferes with spermatogenesis
(32). The decrease in testosterone may be a
direct effect of glucocorticoids on testosterone
biosynthesis (33).
Chronic Disease
Gonadal dysfunction is frequent in men and
women with systemic disorders such as renal
failure, liver cirrhosis, sickle cell anemia (34),
chronic respiratory disease, gastrointestinal
disease, or cancer (35), and with severe infec-
tions such as malaria or pneumonia (28). The
mechanisms involved are often multiple
(hypoxia, altered hormonal clearance, fever,
nutritional status, or drugs). Acute illness
(brain trauma, myocardial infarction, or elec-
tive surgery) is usually associated with tempo-
rary hypogonadotropic hypogonadism (35).
Both primary and secondary hypogonadism
may occur (35). In addition, the euthyroid
sick syndrome (low T3, normal or low T4,
and normal TSH) is common in chronic dis-
ease, and its degree often correlates with the
seriousness of the underlying disease (36).
Deleterious Effects of
Hormonal Imbalance in Adults
Normal ranges for hormone levels are usually
defined as those levels not associated with
pathologic symptoms. These ranges are used to
set thresholds convenient for clinical use and
diagnostic or therapeutic decisions. However,
as is true for most or all physiologic functions,
a continuum connects the physiologic and
pathologic levels, which often overlap. This
explains the development of dynamic tests that
assess the response to hormonal challenge,
though they are also bound by arbitrary criteria
of normal responses. In this section we
describe some of the health outcomes associ-
ated with relatively mild hormone perturba-
tion. In addition, it is well established that
menstrual cycles and sexual function may be
indirectly disturbed in many endocrine condi-
tions—for example, hypo- or hyperthyroidism
(37), diabetes (38), and pituitary tumors that
secondarily affect the gonadal axis. This can
occur in women as well as in men (34,35) and
illustrates the interrelationship of the different
endocrine systems. However, the individual
susceptibility to gonadal imbalance caused by
other endocrinopathies is variable. For exam-
ple, some women have adverse gonadal effects
caused by only mild endocrine disease, whereas
others are still fertile despite major imbalance.
Borderline Hypo- and Hyperthyroidism
Longstanding borderline or mild hypo- or
hyperthyroidism has been linked to potential
adverse health effects, and therapy for these
disorders is generally recommended (39).
Subclinical or mild hypothyroidism is com-
mon in women and in the elderly and has been
associated with alteration in the lipoprotein
proﬁle, such as increased cholesterol, and with
increased incidence of depression by lowering
of the threshold for the development of major
depressive disorders (40) and other mood dis-
orders (41,42). In addition, mild hypothy-
roidism has been linked with diminished
response to standard psychiatric treatment
and with cognitive dysfunction (41). A 0.26
ng/dL geometric mean difference in free T4
in women during the second trimester of
pregnancy has been associated with an aver-
age 4-point IQ reduction in their children
(0.97 ng/dL vs. 0.72 ng/dL; p < 0.001) (43).
Cases (n = 62) were selected from among
25,216 pregnant women with serum TSH
levels at or above the 98th percentile with
matched controls (n = 124). These results
reveal the sensitivity of brain development to
thyroid hormones. 
Subclinical hyperthyroidism, which can
be observed in patients with toxic thyroid
nodule or on suppressive thyroid hormone
therapy, may cause bone demineralization,
particularly in postmenopausal women
(40,44). Cortical bone is more affected than
trabecular bone, but it is uncertain whether
the overall risk of fracture is increased (45).
Mild hyperthyroidism also confers a 3-fold
relative risk for the development of atrial ﬁb-
rillation (40). In addition, other cardiac
changes have been reported in middle-aged
patients (average age 39 years) on suppressive
therapy (46): increased heart rate, premature
atrial contractions, changes in left ventricular
mass, and enhanced velocity of ventricular
shortening. At this point, it is unclear
whether these changes have deleterious clini-
cal consequences (44).
Glucose Intolerance
Glucose intolerance is an intermediate cate-
gory between normal glucose tolerance and
overt diabetes and represents a gray area
between normal and clearly pathologic glu-
cose homeostasis associated with the risk of
specific diabetic complications. A dynamic
test such as a glucose challenge test is needed
to diagnose this intermediate state. Glucose
intolerance is common, with an incidence
varying widely (2–25%) among populations
(47). It is a risk factor for atherosclerosis (48)
and overt diabetes. It is also associated with
insulin resistance, which is part of the meta-
bolic syndrome that includes hypertension,
central obesity, hyperinsulinemia, and hyper-
lipidemia (48). Some preliminary data sug-
gest an association between glucose
intolerance and autonomic neuropathy (49). 
Mild Hyperprolactinemia
Mild hyperprolactinemia has a negative
signiﬁcant impact on the gonadal axis in both
women and men. Prolactin is mildly elevated
in primary hypothyroidism, polycystic ovaries,
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and stress, in patients using neuroleptic and
other antidopaminergic drugs, in patients with
acromegaly or pituitary macroadenomas com-
pressing the infundibulum, and in patients
with renal failure (50). Often no speciﬁc cause
is found and this hyperprolactinemia is called
functional. Mild hyperprolactinemia has also
been linked to an increased risk of auto-
immune disease (51).
Mild Hyperandrogenism
Mild increased secretion of androgens is the
most common endocrinopathy in women,
affecting 10–20% of women (52). It origi-
nates from the adrenal gland or the ovary.
Beyond the cosmetic aspects of acne, hir-
sutism, androgenic alopecia (male-pattern
hair loss) and their psychologic consequences,
this hyperandrogenism may disrupt normal
gonadal function and cause menstrual irregu-
larity. The degree of menstrual irregularity is
directly linked to the degree of hyperandro-
genism. In fact, there is a direct correlation
between testosterone levels and the length of
the follicular phase, and an indirect correla-
tion with the length of the luteal phase (53).
Hyperandrogenic women with polycystic
ovarian syndrome experience obesity, various
degrees of insulin resistance, and unfavorable
lipid patterns (52). Interestingly, in a signiﬁ-
cant subgroup of women with clinical hyper-
androgenism, androgen levels are normal,
suggesting an increased end-organ sensitivity
to androgens (52). This is important because
for this subgroup of subjects, the observed
effect may come from receptor dysfunction or





Beyond the evident effects on reproduction,
there also are systemic negative effects of
gonadal imbalance. One of the most studied
effects today is the increased risk of osteo-
porosis (54). The occurrence of hypoestro-
genic amenorrhea in young women prevents
the reaching of peak bone mass and later
leads to an increased risk of osteoporosis (55)
or even fractures (54). Speciﬁcally, adolescent
girls with oligomenorrhea and amenorrhea,
whether linked (56) or not (57) to exercise or
eating disorders, are at risk for osteopenia.
Interestingly, cyclic treatment with a proges-
tative (medroxyprogesterone) to mimic nor-
mal cycles in women with irregular cycles
may increase bone density (58). These pre-
liminary data suggest that not only estrogen
per se but also an optimal ratio of estrogen to
progesterone could signiﬁcantly help prevent
osteoporosis in premenopausal women.
Hypoestrogenic amenorrhea is also associated
with adverse alterations of the lipoprotein
proﬁles and consequently an increased risk of
cardiovascular events (54). 
The beneficial effects of estrogens on
cognition and mood have also recently been
recognized in postmenopausal women (59).
More strikingly, breast, ovarian, and endome-
trial uterine cancers are all recognized as
hormone-dependent cancers (60). Mild hor-
monal imbalance, exogenous hormonal
administration (oral contraception or estrogen
replacement therapy after menopause), and
sheer physiologic events such as the occur-
rence of pregnancies or the age at ﬁrst menses
are involved, showing that in those cases there
may be no threshold for the risk of cancer. In
breast cancer, for example, epidemiologic
studies (60–62) have shown that the risk is
linked to different parameters integrating the
lifetime duration of exposure to estrogens (i.e.,
age at ﬁrst menses, menopause, and pregnan-
cies). Inadequate luteal levels unable to oppose
estrogen levels may also be a factor (61).
Interestingly, pregnancy seems to have two
discordant effects on the risk of breast cancer.
Epidemiologic studies have shown that a com-
pleted pregnancy seems to decrease the risk,
whereas ﬁrst-trimester interrupted pregnancies
are associated with an increased risk (60). A
more recent study demonstrates that the dual
effect of pregnancy could be explained by the
long-term protective effect against cancer and
a short-term increase in risk after each preg-
nancy (62). In addition, it is suggested that
the higher risk of postmenopausal breast
cancer in obese women is linked to the arom-
atization of androgens into estrone in the adi-
pose tissue (61). Differences in international
rates of breast cancer have also been linked to
differences in estrogen levels (61). Ovarian
cancer is more frequent in infertile or nulli-
parous women, whereas the use of contracep-
tive pills is associated with a lesser risk (63).
These results led to the theory of “incessant
ovulation” for ovarian carcinogenesis (64).
Finally, it is well established that endometrial
carcinoma is a hormonally determined dis-
ease, usually occurring after menopause (63).
In addition, anovulatory amenorrhea, with its
hormonal profile characterized by very low
levels of progesterone and subnormal levels of
estrogen, increases the risk of endometrial
hyperplasia and carcinoma even in young
women (54). Of course, other risk factors are
involved, such as genetic predisposition or
diet (60).
Debate over estrogen replacement therapy
after menopause with doses supposed only to
expand the duration of normal female estro-
gen and progesterone exposure is often heated
because treatment seems to carry both bene-
fits and risks. Treatment decisions usually
stem from the intensity of menopausal symp-
toms, risk factors for hormonal cancer and
osteoporosis, a woman’s preference, and also
the physician’s attitude. The difficulty of
giving a clear answer to a given woman illus-
trates well the controversy linked to hor-
monal effects, even when replacement targets
are within physiologic ranges. 
Medical Thresholds
The concept of threshold or of a variable
threshold is used routinely in medicine when
criteria are set for diagnosis and therapeutic
intervention. Determination of a threshold is
complicated because typically there is overlap
in clinical values such that affected persons
may have values within the normal range and
unaffected persons may have values outside
the normal range. Therefore, diagnostic
threshold criteria are relatively arbitrary cutoff
values, representing a balance between the
ability of the screen to detect truly affected
persons (sensitivity) and the appropriate cate-
gorization of nonaffected persons (speciﬁcity).
Continuous variables such as blood
glucose (65) or cholesterol (66) illustrate well
the continuum in the risk associated with a
given parameter. We have already discussed
the relationship between glucose tolerance
and cardiovascular disease. Indeed, several
epidemiologic studies show that there is no
threshold for the link between glycemia and
cardiovascular disease (65,67). The authors of
the Framingham Offspring Study concluded,
“Metabolic risk factors for Type 2 diabetes
mellitus and for cardiovascular disease worsen
continuously across the spectrum of glucose
tolerance categories, beginning in the lowest
quintiles of normal fasting glucose level” (65). 
Diagnostic procedures and the decision to
proceed with therapeutic intervention, which
deﬁnes therapeutic thresholds, are also inﬂu-
enced by other factors, including life stage
and the presence of other risk factors. For
example, during pregnancy, the screening for
gestational diabetes uses both different test
and cutoff values of blood glucose (Table 1)
(68) because during pregnancy the outcome
of the fetus also must be taken into account.
Gestational diabetes is associated with signiﬁ-
cant maternal and fetal morbidity and long-
term consequences for the offspring
(increased weight, glucose intolerance, or
even poorer intellectual performance, and
psychomotor development) (69–71). Fetal
and neonatal hyperinsulinemia in offspring of
diabetic mothers causes immediate neonatal
hypoglycemia and subsequent development
of childhood obesity and glucose intolerance
(69). In addition, although criteria for deter-
mining hypertension are highly debated (72),
the criteria for treating hypertension are also
more stringent in diabetic than in nondia-
betic patients (73). Thresholds for therapeutic
interventions should indeed be tailored for
some groups of patients. In summary, there
may be no threshold for a given risk; but
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from a practical point of view, thresholds are
set both for diagnostic and therapeutic pur-
poses. The history of medicine has shown
that their fate is to be revisited in the light of
new science. 
What is well recognized for parameters
such as blood glucose, lipids, or blood pres-
sure mentioned above is also quite valid for
hormonal levels in general. Indeed, in some
cases, adverse effects occur when hormone
levels are still in the normal ranges deﬁned for
a population but are in fact elevated for a
given individual. This is illustrated by the
occurrence of suppressed TSH (a sign of
hyperthyroidism) associated with levels of
thyroid hormones in the upper side of the
normal range. Furthermore, when one
assesses a risk for a given individual or popu-
lation, one should also consider other risk fac-
tors and use clinical judgment. For example,
in geographic regions of iodine deficiency,
individuals with a genetic predisposition to
thyroid disease may not be able to compen-
sate for an additional thyroid stressor. In
addition, chemicals with the potential to dis-
rupt thyroid homeostasis may have more sig-
niﬁcant health effects in such regions. In this
respect, clinical experience may provide guid-
ance for decision making regarding EDCs. 
Implications for Testing of
Endocrine-Disrupting
Chemicals 
The application of the threshold assumption,
commonly used in toxicology, to endocrine-
disruptor testing may be problematic because
the endocrine system at baseline has already
achieved physiologic threshold (the effects
observed with hormones within the physio-
logic range), which is the basis of normal hor-
monal function. Therefore, if a risk is already
associated with background endogenous lev-
els of hormones, then a threshold for an
adverse effect may already have been reached,
and any additional hormonally active com-
pound is potentially harmful, at least for a
susceptible subgroup of the population (74).
This may well be the case for the risk of
breast cancer. The notion of individual
susceptibility is important and encompasses
many factors, e.g., genetic susceptibility to
cancer or autoimmune disease, receptor func-
tion, environmental factors such as diet (fat,
iodine content) or chemical exposure.
Recently, the no-threshold hypothesis was
tested with turtle eggs, in which sex determi-
nation normally is temperature dependent
but can be altered by exogenous estrogen
exposure. In this study, even the lowest dose
of estradiol applied to eggs (400 pg/egg or
~ 40 ng/kg) resulted in sex reversal in 14.5%
of the eggs (74).
In light of the clinical experience in
endocrine disease reviewed above, we con-
sider that traditional toxicologic low-dose
testing (at best in the parts per million range),
although appropriate for testing carcinogenic
effects, may not be suitable for determining
endocrine effects. Furthermore, although it is
difficult to assess and extrapolate from one
species to another, it is also important to
expand the study spectrum to more sensitive
end points, especially those relevant to
endocrine effects. This could include, for
example, bone mineralization, relevant for
thyroid, gonadal, and adrenal systems;
detailed cardiac and metabolic function; and
behavior and cognitive functions. 
In our view, the data presented for adults
are already compelling. It is likely that the
human embryo and/or fetus, having less
built-in compensatory capacity than an adult,
may often be more vulnerable to any exoge-
nous or endogenous endocrine disturbance.
Indeed, the placenta does not provide the
protection that was assumed in the past. This
is illustrated by measurements of detectable
levels of synthetic chemicals in cord blood,
reflecting placental transfer. Consequently,
special attention is required when testing
endocrine developmental toxicity.
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Table 1. Screening protocols for diabetes outside and during pregnancy.
During pregnancy
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